| 1 |
吴宗盛，谢剑锋，邱海波.2021 版拯救脓毒症运动指南：早期复苏的八大“陷阱” ［J/OL］.中华重症医学电子杂志，2023，9（1）：14-18.
|
| 2 |
薛月川，隆云.从血流到功能的距离 ［J/OL］.中华重症医学电子杂志，2024，10（3）：209-213.
|
| 3 |
Muñoz F，Born P，Bruna M，et al.Coexistence of a fluid responsive state and venous congestion signals in critically ill patients：a multicenter observational proof-of-concept study ［J］.Crit Care，2024，28（1）：52.
|
| 4 |
Kattan E，Castro R，Miralles-Aguiar F，et al.The emerging concept of fluid tolerance：a position paper ［J］.J Crit Care，2022，71：154070.
|
| 5 |
刘一娜，马晓春.脓毒症性心肌病的血管活性药物选择 ［J/OL］.中华重症医学电子杂志，2020，6（2）：128-131.
|
| 6 |
Jung RG，Di Santo P，Mathew R，et al.Arrhythmic events and mortality in patients with cardiogenic shock on inotropic support：results of the DOREMI randomized trial ［J］.Can J Cardiol，2023，39（4）：394-402.
|
| 7 |
Lewis TC，Aberle C，Altshuler D，et al.Comparative effectiveness and safety between Milrinone or Dobutamine as initial inotrope therapy in cardiogenic shock ［J］.J Cardiovasc Pharmacol Ther，2019，24（2）：130-138.
|
| 8 |
Feneck RO，Sherry KM，Withington PS，et al.Comparison of the hemodynamic effects of milrinone with Dobutamine in patients after cardiac surgery ［J］.J Cardiothorac Vasc Anesth，2001，15（3）：306-315.
|
| 9 |
Mathew R，Di Santo P，Jung RG，et al.Milrinone as compared with Dobutamine in the treatment of cardiogenic shock ［J］.N Engl J Med，2021，385（6）：516-525.
|
| 10 |
Cholley B，Bojan M，Guillon B，et al.Overview of the current use of levosimendan in France：a prospective observational cohort study ［J］.Ann Intensive Care，2023，13（1）：69.
|
| 11 |
Mehta RH，Leimberger JD，van Diepen S，et al.Levosimendan in patients with left ventricular dysfunction undergoing cardiac surgery［J］.N Engl J Med，2017，376（21）：2032-2042.
|
| 12 |
Gordon AC，Perkins GD，Singer M，et al.Levosimendan for the prevention of acute organ dysfunction in sepsis ［J］.N Engl J Med，2016，375（17）：1638-1648.
|
| 13 |
Christie S，Deyell MW.Inotropes and arrhythmias：are we doing harm or guilt by association? ［J］.Can J Cardiol，2023，39（4）：403-405.
|
| 14 |
Evans L，Rhodes A，Alhazzani W，et al.Surviving Sepsis Campaign：international guidelines for management of sepsis and septic shock 2021 ［J］.Intensive Care Med，2021，47（11）：1181-1247.
|
| 15 |
Kattan E，Ibarra-Estrada M，Jung C.Knowing the ropes of vasopressor dosing：a focus on norepinephrine ［J］.Intensive Care Med，2024，50（4）：587-589.
|
| 16 |
McIntyre WF，Um KJ，Alhazzani W，et al.Association of vasopressin plus catecholamine vasopressors vs catecholamines alone with atrial fibrillation in patients with distributive shock：a systematic review and meta-analysis ［J］.JAMA，2018，319（18）：1889-1900.
|
| 17 |
Bellomo R，Forni LG，Busse LW，et al.Renin and survival in patients given angiotensin ⅱ for catecholamine-resistant vasodilatory shock.A clinical trial ［J］.Am J Respir Crit Care Med，2020，202（9）：1253-1261.
|
| 18 |
Leisman DE，Fernandes TD，Bijol V，et al.Impaired angiotensin Ⅱtype 1 receptor signaling contributes to sepsis-induced acute kidney injury ［J］.Kidney Int，2021，99（1）：148-160.
|
| 19 |
Ibarra-Estrada M，Kattan E，Aguilera-González P，et al.Early adjunctive methylene blue in patients with septic shock：a randomized controlled trial ［J］.Crit Care，2023，27（1）：110.
|
| 20 |
李莉，张丽娜，钱招昕.亚甲蓝——脓毒症休克的“魔法锦囊”？［J/OL］.中华重症医学电子杂志，2024，10（2）：136-142.
|
| 21 |
张引，李国强.亚甲蓝治疗脓毒症休克的研究进展 ［J/OL］.中华重症医学电子杂志，2024，10（2）：143-147.
|
| 22 |
Arabi YM，Belley-Cote E，Carsetti A，et al.European Society of Intensive Care Medicine clinical practice guideline on fluid therapy in adult critically ill patients.Part 1：the choice of resuscitation fluids ［J］.Intensive Care Med，2024，50（6）：813-831.
|
| 23 |
Myburgh JA，Mythen MG.Resuscitation fluids ［J］.N Engl J Med，2013，369（25）：2462-2463.
|
| 24 |
Finfer S，Bellomo R，Boyce N，et al.A comparison of albumin and saline for fluid resuscitation in the intensive care unit ［J］.N Engl J Med，2004，350（22）：2247-2256.
|
| 25 |
Woodcock TE，Woodcock TM.Revised Starling equation and the glycocalyx model of transvascular fluid exchange：an improved paradigm for prescribing intravenous fluid therapy ［J］.Br J Anaesth，2012，108（3）：384-394.
|
| 26 |
Adamson RH，Lenz JF，Zhang X，et al.Oncotic pressures opposing filtration across non-fenestrated rat microvessels ［J］.J Physiol，2004，557（Pt 3）：889-907.
|
| 27 |
Pries AR，Secomb TW，Gaehtgens P.The endothelial surface layer ［J］.Pflugers Arch，2000，440（5）：653-666.
|
| 28 |
Kitasato L，Yamaoka-Tojo M，Iwaya T，et al.Rivaroxaban as a protector of oxidative stress-induced vascular endothelial glycocalyx damage via the IQGAP1/PAR1-2/PI3K/Akt pathway ［J］.J Vasc Res，2025，62（1）：22-36.
|
| 29 |
Soubihe Neto N，de Almeida M，Couto HO，et al.Biomarkers of endothelial glycocalyx damage are associated with microvascular dysfunction in resuscitated septic shock patients ［J］.Microvasc Res，2024，154：104683.
|
| 30 |
Zhan JH，Wei J，Liu YJ，et al.Sepsis-associated endothelial glycocalyx damage：a review of animal models，clinical evidence，and molecular mechanisms ［J］.Int J Biol Macromol，2025：139548.Online ahead of print.
|
| 31 |
Durand F，Kellum JA，Nadim MK.Fluid resuscitation in patients with cirrhosis and sepsis：a multidisciplinary perspective ［J］.J Hepatol，2023，79（1）：240-246.
|
| 32 |
Valerio C，Theocharidou E，Davenport A，et al.Human albumin solution for patients with cirrhosis and acute on chronic liver failure：beyond simple volume expansion ［J］.World J Hepatol，2016，8（7）：345-354.
|
| 33 |
Pompili E，Zaccherini G，Piano S，et al.Real-world experience with long-term albumin in patients with cirrhosis and ascites ［J］.JHEP Rep，2024，6（12）：101221.
|
| 34 |
Trebicka J，Garcia-Tsao G.Controversies regarding albumin therapy in cirrhosis ［J］.Hepatology，2025，81（1）：288-303.
|
| 35 |
Kalo E，Read S，Baig A，et al.Efficacy of albumin use in decompensated cirrhosis and real-world adoption in Australia ［J］.JGH Open，2024，8（9）：e70029.
|
| 36 |
Freitas F，Hammond N，Li Y，et al.Resuscitation fluid practices in Brazilian intensive care units：a secondary analysis of Fluid-TRIPS ［J］.Rev Bras Ter Intensiva，2021，33（2）：206-218.
|
| 37 |
Finfer S，Myburgh J，Bellomo R.Intravenous fluid therapy in critically ill adults ［J］.Nat Rev Nephrol，2018，14（9）：541-557.
|
| 38 |
Soussi S，Ferry A，Chaussard M，et al.Chloride toxicity in critically ill patients：what’s the evidence? ［J］.Anaesth Crit Care Pain Med，2017，36（2）：125-130.
|
| 39 |
Morgan TJ.The ideal crystalloid - what is ‘balanced’? ［J］.Curr Opin Crit Care，2013，19（4）：299-307.
|
| 40 |
Ramming S，Shackford SR，Zhuang J，et al.The relationship of fluid balance and sodium administration to cerebral edema formation and intracranial pressure in a porcine model of brain injury ［J］.J Trauma，1994，37（5）：705-713.
|
| 41 |
Rowell SE，Fair KA，Barbosa RR，et al.The impact of pre-hospital administration of lactated Ringer’s solution versus normal saline in patients with traumatic brain injury ［J］.J Neurotrauma，2016，33（11）：1054-1059.
|
| 42 |
Lombardo S，Smith MC，Semler MW，et al.Balanced crystalloid versus saline in adults with traumatic brain injury：secondary analysis of a clinical trial ［J］.J Neurotrauma，2022，39（17-18）：1159-1167.
|
| 43 |
Scolletta S，Bodson L，Donadello K，et al.Assessment of left ventricular function by pulse wave analysis in critically ill patients ［J］.Intensive Care Med，2013，39（6）：1025-1033.
|
| 44 |
Messina A，Romano SM，Bonicolini E，et al.Cardiac cycle efficiency and dicrotic pressure variations：new parameters for fluid therapy：an observational study ［J］.Eur J Anaesthesiol，2017，34（11）：755-763.
|
| 45 |
Chandrasekhar A，Padrós-Valls R，Pallarès-López R，et al.Tissue perfusion pressure enables continuous hemodynamic evaluation and risk prediction in the intensive care unit ［J］.Nat Med，2023，29（8）：1998-2006.
|
| 46 |
Komorowski M，Celi LA，Badawi O，et al.The artificial intelligence clinician learns optimal treatment strategies for sepsis in intensive care［J］.Nat Med，2018，24（11）：1716-1720.
|